Assembly of the membrane attack complex promotes decay of the alternative pathway C3 convertase on Neisseria gonorrhoeae.
C3, C4, factor B, properdin, and C2 binding to serum-sensitive and serum-resistant gonococci was quantitated in C8-deficient and normal human serum by using fluorescein-conjugated antibodies and 3H-labeled components. Organism and serum-specific differences were noted, the most striking of which involved factor B and properdin binding to the serum-sensitive strains in the different sera. C3 binding to these organisms was quantitatively and kinetically equivalent in C8-deficient and normal human serum. In contrast, factor B and properdin binding reached a plateau after 5 min in C8-deficient serum but peaked and fell to control values in normal human serum. Identical results were obtained with normal human serum immunochemically depleted of C8. Between 7 and 15% of the bound C3 participated in formation of the alternative pathway convertase C3bBb/P. Reconstitution of the C cascade by adding purified C8 to C8-deficient serum led to the loss of factor B previously bound to the organisms. Factor B loss occurred coincident with bacterial killing and membrane disruption as observed by electron microscopy. Prevention of membrane disruption by depleting normal human serum of lysozyme had no effect on killing and failed to prevent factor B loss. Stabilization of the C3bBb complex with Ni2+ prevented factor B loss as well as gross membrane disruption but not bacterial killing. C2 (the classical pathway analog of factor B) binding to gonococci was equivalent in C8-deficient and normal human serum peaking within 2.5 min and falling to control values in both sera thereafter. We conclude that the assembly of the membrane attack complex promotes decay of C3bBb/P with release of factor B and properdin but not C3 from the organism surface. Membrane disruption does not appear to be required for this effect. This activity may represent a mechanism to limit continued C consumption.
D001770:Blood Bactericidal Activity / Q000187:drug effects; D003166:Complement Activating Enzymes / Q000097:blood*; D003167:Complement Activation; D050577:Complement C3-C5 Convertases / Q000097:blood*; D011415:Complement Factor B / Q000378:metabolism; D015938:Complement Membrane Attack Complex; D003171:Complement Pathway, Classical; D003165:Complement System Proteins / Q000172:deficiency / Q000378:metabolism*; D005260:Female; D006801:Humans; D007700:Kinetics; D016177:Macrophage-1 Antigen; D008297:Male; D009344:Neisseria gonorrhoeae / Q000276:immunology / Q000378:metabolism* / Q000648:ultrastructure; D009532:Nickel; D011951:Receptors, Complement / Q000032:analysis / Q000378:metabolism
D015938:Complement Membrane Attack Complex; D016177:Macrophage-1 Antigen; D011951:Receptors, Complement; D009532:Nickel; D003165:Complement System Proteins; D003166:Complement Activating Enzymes; D050577:Complement C3-C5 Convertases; D011415:Complement Factor B